513 related articles for article (PubMed ID: 27514317)
1. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
3. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
4. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
5. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
[TBL] [Abstract][Full Text] [Related]
8. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
9. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
10. Early conversion to belatacept after renal transplantation.
Nair V; Liriano-Ward L; Kent R; Huprikar S; Rana M; Florman SS; Delaney VB; Menon MC; Sehgal V; Miko L; Khaim R; Benvenisty A; Lerner S; Arvelakis A; Wadhera V; Ames S; Shapiro R
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28267882
[TBL] [Abstract][Full Text] [Related]
11. Does belatacept improve outcomes for kidney transplant recipients? A systematic review.
Talawila N; Pengel LH
Transpl Int; 2015 Nov; 28(11):1251-64. PubMed ID: 25965549
[TBL] [Abstract][Full Text] [Related]
12. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
13. Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors.
Dürr M; Lachmann N; Zukunft B; Schmidt D; Budde K; Brakemeier S
Transplant Proc; 2017 Oct; 49(8):1747-1756.e1. PubMed ID: 28923620
[TBL] [Abstract][Full Text] [Related]
14. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
15. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R
Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681
[TBL] [Abstract][Full Text] [Related]
16. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
17. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
[TBL] [Abstract][Full Text] [Related]
18. Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2): a retrospective cohort study.
Bertrand D; Matignon M; Morel A; Ludivine L; Lemoine M; Hanoy M; Roy FL; Nezam D; Hamzaoui M; de Nattes T; Moktefi A; François A; Laurent C; Etienne I; Guerrot D
Nephrol Dial Transplant; 2023 Feb; 38(2):481-490. PubMed ID: 35544123
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
20. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.
Gupta G; Regmi A; Kumar D; Posner S; Posner MP; Sharma A; Cotterell A; Bhati CS; Kimball P; Massey HD; King AL
Am J Transplant; 2015 Oct; 15(10):2726-31. PubMed ID: 25988397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]